Advancing Clinical Validation: A New Milestone for HepatoPredict

We are thrilled to announce that an important clinical validation of our Hepatocellular carcinoma (HCC) prognostic tool, HepatoPredict, has been published in the journal Cancers. This study highlights how HepatoPredict can help ensure equitable and accurate patient selection for liver transplantation, fostering fair organ allocation, and improving patient outcomes.

Conducted in collaboration with Centro Hospitalar e Universitário de Coimbra (Coimbra, Portugal), Hospital Universitari i Politècnic La Fe (Valencia, Spain), and Hospital Curry Cabral (Lisbon, Portugal), the research demonstrated how HepatoPredict outperforms existing clinical criteria for patient selection, particularly in terms of negative predictive value, effectively addressing key limitations in current strategies. Notably, the prognostic accuracy of HepatoPredict remained largely unaffected by intra-nodule and intra-patient tumor heterogeneity, highlighting its robustness and reliability even when biopsies were taken from smaller or non-dominant nodules.

This work reaffirms our dedication to developing the best precision medicine solutions for HCC.

The full article is available at: https://www.mdpi.com/2072-6694/17/3/500